Posterske teme Poster topics - Biochemia Medica
Posterske teme Poster topics - Biochemia Medica
Posterske teme Poster topics - Biochemia Medica
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
P14-1 (UP5-1) Onkologija i tumorski biljezi<br />
P14 – Onkologija i tumorski biljezi, P14-1 (UP5-1)<br />
Je li Ca 19-9 XR bolji?<br />
Krajnović-Tomašić V<br />
Opća bolnica Dr. Josip Benčević, Slavonski Brod, Hrvatska<br />
Ca 19-9 je glikoprotein velike molekularne mase poznat<br />
kao mucin. To je antigen koji je povišen u serumu osoba<br />
s raznim gastrointestinalnim karcinomima. Može biti povišen<br />
u stanjima kao što su hepatitis, ciroza, pankreatitis,<br />
kao i kod cistične fi broze. Rabi se kao pomoć u praćenju<br />
bolesnika s karcinomom gušterače ili drugim gastrointestinalnim<br />
karcinomima. Prije nekoliko mjeseci počeli<br />
smo rabiti novi test Ca 19-9 XR. Proizvođač je uz novi test<br />
poslao obavijest da je Ca 19-9 XR poboljšan u smislu povećane<br />
kliničke specifi čnosti, poglavito kod nemalignih<br />
bolesti, ali mu je zadržana ista osjetljivost. Izveli smo usporedno<br />
određivanje s prethodnim testom Ca 19-9 kako<br />
bismo ustanovili postoje li razlike u rezultatima. Određivanje<br />
je izvršeno testovima Ca 19-9 i Ca 19-9 XR tehnologijom<br />
CMIA na analizatoru Architect i2000 SR tvrtke<br />
Abbott. Dobiveni rezultati su razvrstani u skupine: zdravi,<br />
bolesni – nemaligne bolesti, početno ispitivanje bolesnika,<br />
maligne bolesti i maligne bolesti – poslijeoperacijski.<br />
Analiza rezultata navodi na zaključak kako postoje značajne<br />
razlike u dobivenim rezultatima kod nemalignih bolesti,<br />
dok su se kod malignih bolesti rezultati dobro slagali. S<br />
obzirom na različitosti u samom testu prethodni rezultati<br />
dobiveni pomoću Ca 19-9 i novi pomoću Ca 19-9 XR ne<br />
mogu se uspoređivati.<br />
E-mail: vera.krajnovic@vip.hr<br />
P14-2<br />
MTHFR u karcinomu prostate i benignoj<br />
hiperplaziji prostate<br />
Nikolac N 1 , Šimundić AM 1 , Reljić A 2 , Štefanović M 1 , Topić E 1<br />
1 Klinički zavod za kemiju, KB Sestre milosrdnice, Zagreb, Hrvatska<br />
2 Klinika za urologiju, KB Sestre milosrdnice, Zagreb, Hrvatska<br />
Metilentetrahidrofolat-reduktaza (MTHFR) je najvažniji<br />
enzim uključen u procese metilacije DNA i katalizira pretvorbu<br />
5,10-metilentetrahidrofolata u 5-metiltetrahidrofolat.<br />
Polimorfi zam C677T povezan je sa 70%-tnim smanjenjem<br />
aktivnosti enzima i hipometilacijom. Učestalost<br />
<strong>Biochemia</strong> <strong>Medica</strong> 2006;16(Suppl 1):S1–S268<br />
S158<br />
Oncology and tumor markers<br />
P14 – Oncology and tumor markers, P14-1 (UP5-1)<br />
Is Ca 19-9 XR better?<br />
Krajnović-Tomašić V<br />
Dr. Josip Benčević General Hospital, Slavonski Brod, Croatia<br />
Ca 19-9 is a glycoprotein of high molecular weight, known<br />
as mucin. It is an antigen which is elevated in serum of patients<br />
with various gastrointestinal carcinomas, hepatitis,<br />
cirrhosis, pancreatitis, and in cystic fi brosis. It is used as an<br />
aid in monitoring patients with pancreatic carcinoma or<br />
other gastrointestinal carcinomas. The manufacturer has<br />
declared the new Ca 19-9 XR test to have better clinical<br />
specifi city, especially in nonmalignant diseases, while retaining<br />
the same sensitivity. We tested the samples with<br />
both Ca 19-9 and Ca 19-9 XR to see if there were some<br />
diferences. Testing was performed with Ca 19-9 and Ca<br />
19-9 XR tests using CMIA technology on an Architect<br />
i2000 SR analyzer (Abbott). Results were divided into<br />
groups: healthy, disease – nonmalignant, initial testing,<br />
malignant diseases, and malignant diseases – postoperative.<br />
The analysis revealed signifi cant diff erences in the<br />
results in nonmalignant diseases, whereas in malignant<br />
diseases the results showed good concordance. Thus,<br />
the results obtained by Ca 19-9 and Ca 19-9 XR cannot be<br />
compared due to test variation.<br />
E-mail: vera.krajnovic@vip.hr<br />
P14-2<br />
MTHFR in prostatic cancer and benign<br />
prostatic hyperplasia<br />
Nikolac N 1 , Šimundić AM 1 , Reljić A 2 , Štefanović M 1 , Topić E 1<br />
1 University Department of Chemistry, Sestre milosrdnice University<br />
Hospital, Zagreb, Croatia<br />
2 University Department of Urology, Sestre milosrdnice University<br />
Hospital, Zagreb, Croatia<br />
Methylenetetrahydrofolate reductase (MTHFR) is the<br />
most important enzyme involved in DNA methylation<br />
process and converts 5,10-methylenetetrahydrofolate to<br />
5-methyltetrahydrofolate. The C677T polymorphism of<br />
the MTHFR gene is associated with 70% lower enzyme
Change language